Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + paclitaxel + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen, consisting of doxorubicin, paclitaxel, and cyclophosphamide, was investigated by the M.D. Anderson Cancer Center for the treatment of metastatic or recurrent breast cancer. The regimen utilizes a dose-intense schedule, which involves administering higher doses of cytotoxic agents over a compressed timeframe to overcome drug resistance and maximize tumor cell kill. Because of the significant myelosuppression associated with these doses, the protocol includes supportive care with filgrastim (G-CSF) and peripheral blood stem cell transplantation (PBSCT) to facilitate hematologic recovery. Doxorubicin acts as an anthracycline that inhibits topoisomerase II and intercalates DNA; paclitaxel is a taxane that stabilizes microtubules to induce mitotic arrest; and cyclophosphamide is an alkylating agent that causes DNA cross-linking.
- Other names
- Dose-intense doxorubicin, paclitaxel, and cyclophosphamideDose-intense TAC regimen
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on doxorubicin + paclitaxel + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + paclitaxel + cyclophosphamide.